17,261 trials
COVID-19 (Healthy Volunteers)
Primary: Geometric Mean Titers (GMTs) of Neutralizing Antibodies Against SARS-CoV-2 Recombinant Protein Vaccine Formulations at Day 1 — 5.00; 5.00; 5.00; 5.00 titers
Chronic Delta Hepatitis
Primary: Change From Baseline to Week 24 in Mean Hepatitis D Virus (HDV) Ribonucleic Acid (RNA) Titer — -1.62 log IU/mL
Ovarian Cancer
Primary: Progression Free Survival (PFS) of Combination Platinum Based Therapy With Anti-Programmed Death (PD)-1 Therapy Followed by Maintenance Anti-PD-1 Therapy in Patients…
Dry Eye Disease
Primary: Number of Subjects With Adverse Events — 13; 15; 10 Participants
Anaplastic Large Cell Lymphoma · Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma · Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma
Primary: Number of Patients With Grade 3 or Above Toxicities — 9 Participants
College Student Drinking
Primary: Alcohol Consumption at 3 Months Post-intervention — 4.08; 4.15; 4.89 drinks per week
Cytomegalovirus Positive · Glioblastoma · Gliosarcoma
Primary: Maximum Tolerated Dose (MTD) (Recurrent Glioblastoma Participant Cohort)- Phase I — 3; 3; 3; 7 participants
Hepatocellular Carcinoma
Primary: Number of Participants With Objective Response Rate — 20; 9; 0; 1 Participants
Lymphoma
Primary: Phase 1: Number of Participants With Any Treatment-emergent Adverse Event (TEAE) — 6; 7 Participants
Chronic Heart Failure
Primary: Peak Exercise Wedge Pressure — 44; 34 Mmhg
Relapse/Refractory Multiple Myeloma
Primary: Overall Response Rate (ORR) — 24 Participants
Hereditary Hemochromatosis
Primary: Effect of PTG-300 on Transferrin Saturation — -6.07 percent saturation
Hematologic Neoplasms
Primary: Overall Response Rate (ORR) as Assessed International Workshop on Chronic Lymphocytic Leukemia (IWCLL) 2008: Disease Cohort — 63.3 Percentage of Participants
Gastroparesis
Primary: 4-Week Change in the Postprandial Fullness and Early Satiety Symptoms Severity — -1.16; -1.03 score on a scale — p=0.69
SARS-CoV Infection · COVID-19 · Allergic Reaction
Primary: Proportion of Participants Who Experienced a Systemic Allergic Reaction (CoFAR Grade 2+ Regardless of Tryptase or CoFAR Grade 1 With Elevated Tryptase) Within 90 Minutes…